FREM2 and glioblastoma: On that account, because it was found robust, comparable to IDH mutation status, and superior to MGMT methylation status in most of the comparisons, we propose FREM2 pathway activation as a novel robust predictor of unfavorable prognosis of glioblastoma patients.